| Evaluation of Different HTS Strategies: Pool10 vs. Single Compound Screening |
|
Presentation: 2B01 Session: Comparing HTS TechnologiesUlf Bömer, Drew Sukovich (Berlex Biosciences), Benjamin Bader, Christian Bergsdorf, Manfred Husemann, Gernot Langer, Janet Meurer (Berlex Biosciences), Sofia Ribeiro (Berlex Biosciences), Karsten Parczyk, Michael Snider (Berlex Biosciences), Schering AG Presenting Author: Ulf Bömer, Schering AG - Germany The question whether compounds should be screened individually or in mixtures is present since the beginning of HTS and is still of current interest. Despite of the high importance of the question there are very few publications on the pros and cons of both approaches, especially regarding those taking into account the major changes in screening of the last years (homogeneous assays, uHTS, miniaturization). We have made an in depth cost-benefit-evaluation of pool 10 and single compound screening. For several assays representing the most important target families and HTS assay technologies a diversity selected set of 150.000 was screened in parallel in pool 10 and single compound mode. In the pool 10 mode compounds were tested twice in the presence of 9 different compounds (= orthogonal pooling) whereas in the single compound mode a compound was tested only once. A quantitative analysis of the data will be presented. |